삼성에피스홀딩스
Not investment advice · For research purposes only; not a solicitation or an offer of any financial product. Past statistics do not indicate future outcomes. Facts from filings and public sources; not investment advice. No valuation estimate, direction or trading levels are provided.
① Fact table
Values as filed · consolidated / separate basis per year · no interpretation
| Item | 2025 | Unit |
|---|---|---|
| 매출액 | 251,689,950,548 | KRW |
| 영업이익 | -63,640,615,999 | KRW |
| 당기순이익 | 85,313,155,522 | KRW |
| 자본총계 | 5,905,769,042,165 | KRW |
| 부채총계 | 1,809,815,283,137 | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준)· in house | 30.64 | % |
| Statement basis | Consolidated |
Source: dart_fnltt · Computed in house · card as of 2026-10-13 · Filing date per year: not on the card (see the filing timeline below) · 'in house' marks items computed from the values above
② Profitability breakdown
Arithmetic on the fact table only · same year, same basis · '—' where a value is missing or the denominator is 0 or below · in each panel the bar height maps the span from the most negative to the largest positive value onto the panel height · no interpretation attached
Source: computed in house from the fact table · card as of 2026-10-13
③ My own calculation
A simple residual-income formula. You enter the assumptions; only the base equity is filled in from the filing. The result is computed from your assumptions and is not a figure this site publishes.
V = B₀ + (ROE − r) × B₀ ÷ (1 + r − ω)
Fill in all four boxes to compute. The site fills in nothing but the base equity.
Computed in this browser only; nothing you type is sent or stored.
- 2026-10-06Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-10-01Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (중증 호산구 천식 치료제 SB41(Fasenra 바이오시밀러) 및 유전성 재발열 증후군 치료제 SB44(Ilaris 바이오시밀러) 파트너십 계약 체결) original ↗Source: dart_disclosure
- 2026-09-28Filing title as filed[기재정정]기업지배구조보고서공시 original ↗Source: dart_disclosure
- 2026-09-07Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-08-31Filing title as filed대규모기업집단현황공시[분기별공시(개별회사용)] original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항 original ↗Source: dart_disclosure
- 2026-08-10Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (SB27주(펨브롤리주맙 바이오시밀러) 한국 품목허가 신청) original ↗Source: dart_disclosure
- 2026-08-04Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-08-04Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-08-04Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-07-24Filing title as filed연결재무제표기준영업(잠정)실적(공정공시) original ↗Source: dart_disclosure
- 2026-07-24Filing title as filed연결재무제표기준영업(잠정)실적(공정공시)(자회사의 주요경영사항) original ↗Source: dart_disclosure
- 2026-07-22Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (Nectin4 단백질 표적 고형암 치료제 후보물질 SBE303 연구개발 및 상업화 계약 체결) original ↗Source: dart_disclosure
- 2026-07-10Filing title as filed결산실적공시예고(안내공시) original ↗Source: dart_disclosure
- 2026-07-09Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (개량항체 공동기술개발 및 기술도입 옵션계약 체결) original ↗Source: dart_disclosure
- 2026-07-06Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-06-29Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (SB27(Keytruda 바이오시밀러) 제3상 임상시험 1차 유효성 분석 결과 발표) original ↗Source: dart_disclosure
- 2026-06-08Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-06-01Filing title as filed[기재정정]대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)] original ↗Source: dart_disclosure
| Layer | Badge | n | Note |
|---|---|---|---|
| range | unknown | 0 | 80%·90% 범위의 전향 적중 기록(목표일 개장 전 박제 → 종가 공표 뒤 채점) |
| fair_value | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| direction | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| trade_levels | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| Valuation estimate | not provided | — | Not published: no demonstrated discriminative power |
| Direction (up or down) | not provided | — | Not published: no demonstrated discriminative power |
| Trading levels | not provided | — | Not published: no demonstrated discriminative power |
Why this?
Checking…